Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Adda · SciRah

Researcher profile · Semantic Scholar

N. Adda

Share profile

N. Adda — researcher profile on SciRah

h-index: 23
Works: 74
Citations: 5,798

Most-cited papers

Telaprevir for previously untreated chronic hepatitis C virus infection.
I. Jacobson, J. Mchutchison, G. Dusheiko, A. Di Bisceglie +20 more
2011New England Journal of Medicine2,552 citations Open access
Semantic Scholar
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
K. Sherman, S. Flamm, N. Afdhal, D. Nelson +12 more
2011New England Journal of Medicine796 citations Open access
Semantic Scholar
Telaprevir for previously treated chronic HCV infection.
J. Mchutchison, M. Manns, A. Muir, Norah A. Terrault +11 more
2010New England Journal of Medicine777 citations Open access
Semantic Scholar
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
J. Sullivan, S. De Meyer, D. Bartels, I. Dierynck +13 more
2013Clinical Infectious Diseases191 citations
Semantic Scholar
Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV
M. Sulkowski, Kenneth E. Sherman, D. Dieterich, M. Bsharat +11 more
2013Annals of Internal Medicine145 citations
Semantic Scholar
1369 TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
I. Jacobson, I. Catlett, P. Marcellin, N. Bzowej +9 more
2011122 citations
Semantic Scholar
Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
Corinne Vigouroux, S. Gharakhanian, Y. Salhi, T. H. Nguyen +3 more
1999Diabetes & Metabolism109 citations
Semantic Scholar
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
V. Ratziu, M. Rinella, B. Neuschwander-Tetri, E. Lawitz +10 more
2021Journal of Hepatology107 citations Open access
Semantic Scholar
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
Tara L. Kieffer, S. De Meyer, D. Bartels, J. Sullivan +16 more
2012PLoS ONE97 citations Open access
Semantic Scholar
P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study
G. Dusheiko, L. Bengtsson, N. Adda, R. Kauffman +1 more
2011Gut88 citations Open access
Semantic Scholar
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial
F. Zoulim, C. Fournier, F. Habersetzer, M. Sprinzl +16 more
2019Human Vaccines & Immunotherapeutics78 citations Open access
Semantic Scholar
Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV
M. Sulkowski, Kenneth E. Sherman, D. Dieterich, M. Bsharat +11 more
202064 citations
Semantic Scholar
Retreatment with telaprevir combination therapy in hepatitis C patients with well‐characterized prior treatment response
A. Muir, F. Poordad, J. Mchutchison, M. Shiffman +11 more
2011Hepatology64 citations Open access
Semantic Scholar
EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
A. Ahmad, Kingsley Eze, N. Noulin, V. Horváthová +5 more
2022New England Journal of Medicine53 citations Open access
Semantic Scholar
Pharmacokinetics of Tenofovir Disoproxil Fumarate and Ritonavir-Boosted Saquinavir Mesylate Administered Alone or in Combination at Steady State
G. Chittick, J. Zong, M. Blum, J. Sorbel +3 more
2006Antimicrobial Agents and Chemotherapy48 citations Open access
Semantic Scholar
8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS
J. Sullivan, S. De Meyer, D. Bartels, I. Dierynck +11 more
201146 citations Open access
Semantic Scholar
The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers
V. Garg, Gurudatt Chandorkar, Yijun Yang, N. Adda +4 more
2013British Journal of Clinical Pharmacology43 citations Open access
Semantic Scholar
The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir
V. Garg, R. V. van Heeswijk, Yijun Yang, R. Kauffman +2 more
2012Journal of clinical pharmacology39 citations
Semantic Scholar
Anemia Had No Effect on Efficacy Outcomes in Treatment-NaïVE Patients Who Received Telaprevir-Based Regimen in the Advance and Illuminate Phase 3 Studies
F. Poordad, M. Sulkowski, R. Reddy, A. Di Bisceglie +6 more
201138 citations Open access
Semantic Scholar
477 ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES
M. Sulkowski, R. Reddy, N. Afdhal, A. Di Bisceglie +6 more
201138 citations
Semantic Scholar
1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY
M. Manns, A. Muir, N. Adda, I. Jacobson +9 more
200935 citations
Semantic Scholar
1162 RIBAVIRIN DOSE MODIFICATION IN TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WHO RECEIVED TELAPREVIR COMBINATION TREATMENT: NO IMPACT ON SUSTAINED VIROLOGIC RESPONSE IN PHASE 3 STUDIES
M. Sulkowski, Steven Roberts, N. Afdhal, P. Andreone +8 more
201230 citations
Semantic Scholar
Telaprevir in combination with peginterferon Alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis
D. Dieterich, V. Soriano, K. Sherman, P. Girard +6 more
201224 citations
Semantic Scholar
Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
M. Thompson, H. Kessler, J. Eron, J. Jacobson +6 more
2005AIDS (London)23 citations Open access
Semantic Scholar
4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR
T. Berg, J. Mchutchison, N. Adda, F. Poordad +11 more
201018 citations
Semantic Scholar
55 FUTILITY RULES IN TELAPREVIR COMBINATION TREATMENT
I. Jacobson, D. Bartels, Linda R. Gritz, Tara L. Kieffer +8 more
201215 citations
Semantic Scholar
Long-term Safety and Efficacy Results of Once-Daily Emtricitabine-Based Highly Active Antiretroviral Therapy Regimens in Human Immunodeficiency Virus-Infected Pediatric Subjects
X. Sáez-Llorens, A. Violari, Dalu Ndiweni, R. Yogev +8 more
2008Pediatrics12 citations
Semantic Scholar
1000 A STUDY OF TELAPREVIR (TVR) WITH PEGINTERFERON ALFA-2A (P) AND RIBAVIRIN (R) IN SUBJECTS WITH WELL-DOCUMENTED PRIOR P/R NULL RESPONSE, NON-RESPONSE OR RELAPSE: PRELIMINARY RESULTS
F. Poordad, M. Shiffman, K. Sherman, J. Smith +4 more
200812 citations Open access
Semantic Scholar
LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
E. Coakley, A. Ahmad, Kajal B. Larson, T. Mcclure +9 more
2019Open Forum Infectious Diseases10 citations Open access
Semantic Scholar
Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects
A. Ahmad, K. Sanderson, D. Dickerson, N. Adda
201810 citations
Semantic Scholar
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.
N. Adda, D. Bartels, Linda R. Gritz, Tara L. Kieffer +6 more
2013Clinical Gastroenterology and Hepatology10 citations Open access
Semantic Scholar
Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity
S. Flamm, Andrew J. Muir, M. Fried, K. R. Reddy +10 more
2015Journal of Clinical Gastroenterology9 citations
Semantic Scholar
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
J. Feld, E. Lawitz, Tuan T. Nguyen, J. Lalezari +10 more
2022Antiviral Therapy8 citations Open access
Semantic Scholar
Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin: Analyses of Pre-Defined Subpopulations in the Phase 3 Advance Trial
A. Di Bisceglie, G. Dusheiko, Andrew J. Muir, S. Zeuzem +8 more
20118 citations Open access
Semantic Scholar
594 Ribavirin Dose Modification in Treatment-NaïVE and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies
M. Sulkowski, S. Roberts, N. Afdhal, P. Andreone +8 more
20126 citations Open access
Semantic Scholar
TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
I. Jacobson, I. Catlett, P. Marcellin, N. Bzowej +9 more
20116 citations
Semantic Scholar
Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-NaïVE Patients Regardless of Race or Ethnicity
S. Flamm, R. Reddy, M. Fried, G. Dusheiko +6 more
20116 citations
Semantic Scholar
EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients
Man-Fung Yuen, Wan-Long Chuang, C. Peng, R. Jeng +9 more
2022Journal of Hepatology5 citations
Semantic Scholar
1132 HIGH CONCORDANCE BETWEEN SVR12 AND SVR24 IN PATIENTS RECEIVING TELAPREVIR PLUS PEGINTERFERON AND RIBAVIRIN IN THREE PHASE III CLINICAL TRIALS: ADVANCE, ILLUMINATE AND REALIZE
D. Luo, S. Zeuzem, I. Jacobson, K. Sherman +4 more
20125 citations
Semantic Scholar
415 TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN INCREASED SUSTAINED VIROLOGIC RESPONSE RATES IN TREATMENT-NAIVE PATIENTS REGARDLESS OF RACE OR ETHNICITY
G. Dusheiko, M. Fried, R. Reddy, D. Nelson +6 more
20114 citations
Semantic Scholar
451 TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: ANALYSES OF PRE-DEFINED SUBPOPULATIONS IN THE PHASE 3 ADVANCE TRIAL
P. Marcellin, I. Jacobson, S. Zeuzem, N. Bzowej +8 more
20114 citations
Semantic Scholar
Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
F. Lallemand, N. Adda, V. Schneider, C. Jacomet +2 more
1999Clinical Infectious Diseases4 citations
Semantic Scholar
EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects
Christine Marotta, A. Ahmad, Ed Luo, J. Oosterhaven +2 more
2022Clinical and Translational Science3 citations Open access
Semantic Scholar
EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study
V. Ratziu, M. Rinella, B. Tetri, E. Lawitz +11 more
2020Journal of Hepatology3 citations Open access
Semantic Scholar
Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.
G. Picchio, S. De Meyer, I. Dierynck, A. Ghys +9 more
2014Journal of Clinical Virology3 citations
Semantic Scholar
400 MODELING, CLINICAL AND VIROLOGY DATA FROM PHASE 2 AND 3 STUDIES SUPPORT 12-WEEK TELAPREVIR DURATION IN COMBINATION WITH 24- OR 48-WEEK PEGINTERFERON/RIBAVIRIN DURATION
B. Adiwijaya, Tara L. Kieffer, D. Bartels, G. Picchio +7 more
20113 citations Open access
Semantic Scholar
Assessment of drug–drug interaction potential with EDP‐305, a farnesoid X receptor agonist, in healthy subjects
Alaa Ahmad, N. Adda
2022Clinical and Translational Science2 citations Open access
Semantic Scholar
EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients
J. Feld, E. Lawitz, Tuan T. Nguyen, J. Lalezari +10 more
2022Journal of Hepatology2 citations
Semantic Scholar
Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV and Allowed for Shorter Treatment Duration in Treatment-naive and Prior Relapser Patients
G. Everson, G. Dusheiko, S. Pol, D. Nelson +12 more
20112 citations
Semantic Scholar
Treatment Effect and Resistance Profiles were Similar Between Black/African American and Non-Black/African American Patients Treated with a Telaprevir Combination Regimen
A. Muir, J. Sullivan, G. Dusheiko, M. Fried +9 more
20112 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Bengtsson×18
Invite
L. Bengtsson — researcher profile on SciRah
S. George×16
Invite
S. George — researcher profile on SciRah
R. Kauffman×16
Invite
R. Kauffman — researcher profile on SciRah
S. Zeuzem×15
Invite
S. Zeuzem — researcher profile on SciRah

×13

Invite

I. Jacobson — researcher profile on SciRah

Invite

A. Muir — researcher profile on SciRah

Tara L. Kieffer×10

Invite

Tara L. Kieffer — researcher profile on SciRah

Christopher I. Wright×10

Invite

Christopher I. Wright — researcher profile on SciRah

Invite

K. Sherman — researcher profile on SciRah

M. Sulkowski×8

Invite

M. Sulkowski — researcher profile on SciRah

Invite

G. Picchio — researcher profile on SciRah

Invite

G. Dusheiko — researcher profile on SciRah